Infectious mononucleosis triggers generation of IGG auto-antibodies against native myelin oligodendrocyte glycoprotein

Viruses

Volumn 8, Issue 2, 2016, Pages

  Kakalacheva, Kristina ^a   Regenass, Stephan ^b   Wiesmayr, Silke ^c   Azzi, Tarik ^d   Berger, Christoph ^d   Dale, Russell C ^e   Brilot, Fabienne ^e   Münz, Christian ^a   Rostasy, Kevin ^f   Nadal, David ^d   Lünemann, Jan D ^a,g  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF WITTEN HERDECKE   (Germany)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Autoantibody; Autoimmunity; Epstein barr virus; Infectious mononucleosis; Multiple sclerosis

Indexed keywords

AUTOANTIBODY; IMMUNOGLOBULIN G; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; IMMUNOGLOBULIN M;

ADOLESCENT; ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; MALE; MONONUCLEOSIS; SCHOOL CHILD; AUTOIMMUNE DISEASES; COMPLICATION; IMMUNOLOGY; PRESCHOOL CHILD;

ADOLESCENT; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFECTIOUS MONONUCLEOSIS; MALE; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN;

EID: 84957921466     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8020051     Document Type: Article

References (28)

1. Luzuriaga, K.; Sullivan, J.L. Infectious mononucleosis. N Engl J Med 2010, 362(21), 1993–2000.
2. Balfour, H.H. Jr.; Odumade, O.A.; Schmeling, D.O.; Mullan, B.D.; Ed, J.A.; Knight, J.A.; Vezina, H.E.; Thomas, W.; Hogquist, K.A. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis 2013, 207(1), 80–8.
3. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007, 61(4), 288–99.
4. Ascherio, A.; Munger, K.L.; Lunemann, J.D. The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012, 8(11), 602–12.
5. James, J.A.; Neas, B.R.; Moser, K.L.; Hall, T.; Bruner, G.R.; Sestak, A.L.; Harley, J.B. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum 2001, 44(5), 1122–6.
6. Alotaibi, S.; Kennedy, J.; Tellier, R.; Stephens, D.; Banwell, B.; Epstein-Barr virus in pediatric multiple sclerosis. JAMA 2004, 291(15), 1875–9.
7. James, J.A.; Kaufman, K.M.; Farris, A.D.; Taylor-Albert, E.; Lehman, T.J.; Harley, J.B. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest 1997, 100(12), 3019–26.
8. Reindl, M.; Di Pauli, F.; Rostasy, K.; Berger, T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013, 9(8), 455–61.
9. Dale, R.C.; Tantsis, E.M.; Merheb, V.; Kumaran, R.Y.; Sinmaz, N.; Pathmanandavel, K.; Ramanathan, S.; Booth, D.R.; Wienholt, L.A.; Prelog, K.; Clark, D.R.; Guillemin, G.J.; Lim, C.K.; Mathey, E.K.; Brilot, F. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014, 1(1), e12.
10. Zhou, D.; Srivastava, R.; Nessler, S.; Grummel, V.; Sommer, N.; Bruck, W.; Hartung, H.P.; Stadelmann, C.; Hemmer, B. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A 2006, 103(50), 19057–62.
11. Brilot, F.; Dale, R.C.; Selter, R.C.; Grummel, V.; Kalluri, S.R.; Aslam, M.; Busch, V.; Zhou, D.; Cepok, S.; Hemmer, B. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009, 66(6), 833–42.
12. Bahna, S.L.; Heiner, D.C.; Horwitz, C.A. Sequential changes of the five immunoglobulin classes and other responses in infectious mononucleosis. Int Arch Allergy Appl Immunol 1984, 74(1), 1–8.
13. Cohen, J.I. Epstein-Barr virus infection. N Engl J Med 2000, 343(7), 481–9.
14. Sutton, R.N.; Emond, R.T.; Thomas, D.B.; Doniach, D. The occurrence of autoantibodies in infectious mononucleosis. Clin Exp Immunol 1974, 17(3), 427–36.
15. Rhodes, G.; Rumpold, H.; Kurki, P.; Patrick, K.M.; Carson, D.A.; Vaughan, J.H. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. J Exp Med 1987, 165, 1026–1040.
16. Vaughan, J.H.; Valbracht, J.R.; Nguyen, M.D.; Handley, H.H.; Smith, R.S.; Patrick, K.; Rhodes, G.H. Epstein-Barr virus-induced autoimmune responses. I. Immunoglobulin M autoantibodies to proteins mimicking and not mimicking Epstein-Barr virus nuclear antigen-1. J Clin Invest 1995, 95, 1306–1315.
17. Liebowitz, D.; Kopan, R.; Fuchs, E.; Sample, J.; Kieff, E. An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Mol Cell Biol 1987, 7(7), 2299–308.
18. Meckes, D. G. Jr.; Menaker, N.F.; Raab-Traub, N. Epstein-Barr virus LMP1 modulates lipid raft microdomains and the vimentin cytoskeleton for signal transduction and transformation. J Virol 2013, 87(3), 1301–11.
19. Bretherton, L.; Toh, B.H. IgM autoantibody to intermediate filaments in infectious mononucleosis. J Clin Lab Immunol 1981, 5(1), 7–10.
20. Kataaha, P.K.; Mortazavi-Milani, S.M.; Russell, G.; Holborow, E.J. Anti-intermediate filament antibodies, antikeratin antibody, and antiperinuclear factor in rheumatoid arthritis and infectious mononucleosis. Ann Rheum Dis 1985, 44, 446–449.
21. Sairenji, T.; Nguyen, Q.V.; Woda, B.; Humphreys, R.E. Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen. J Immunol 1987, 138, 2645–2652.
22. Thorley-Lawson, D.A. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 2001, 1(1), 75–82.
23. Tracy, S.I.; Kakalacheva, K.; Lunemann, J.D.; Luzuriaga, K.; Middeldorp, J.; Thorley-Lawson, D.A. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol 2012, 86(22), 12330–40.
24. Bernasconi, N.L.; Traggiai, E.; Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298, 2199–2202.
25. Huggins, J.; Pellegrin, T.; Felgar, R.E.; Wei, C.; Brown, M.; Zheng, B.; Milner, E.C.; Bernstein, S.H.; Sanz, I.; Zand, M.S. CpG DNA activation and plasma-cell differentiation of CD27-naive human B cells. Blood 2007, 109(4), 1611–9.
26. Dorner, M.; Brandt, S.; Tinguely, M.; Zucol, F.; Bourquin, J.P.; Zauner, L.; Berger, C.; Bernasconi, M.; Speck, R.F.; Nadal, D. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. Immunology 2009, 128(4), 573–9.
27. Lim, W.H.; Kireta, S.; Russ, G.R.; Coates, P.T. Human plasmacytoid dendritic cells regulate immune responses to Epstein-Barr virus (EBV) infection and delay EBV-related mortality in humanized NODSCID mice. Blood 2007, 109(3), 1043–50.
28. Fiola, S.; Gosselin, D.; Takada, K.; Gosselin, J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 2010, 185(6), 3620–31.